AMZN
Amazon.com, Inc.
AMZN has the edge over CNNE overall, supported by stronger fundamentals and stronger modeled upside.
CNNE
Cannae Holdings, Inc.
CNNE trails on the overall score without a compensating advantage in the available component scores.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
CNNE Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Stable | |
| Unavailable |
CNNE's cash flow is currently stable, but its revenue and profitability are under pressure. There isn't enough data to rate its balance sheet.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN's PE is in its cheap range at 22x, but its recent earnings include one-off gains. On analysts' estimates for next year's earnings, today's price would be 27x.
CNNE PE Valuation
CNNE has no meaningful PE right now: it lost money over the past year.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
AMZN has the edge over CNNE on the outlook, with more favorable earnings and revenue expectations.
CNNE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Stable | |
| Stable | |
| Limited | |
| Low |
Analysts expect CNNE's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over CNNE on earnings quality, reporting a profit while its opponent remains loss making.
CNNE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.41 | +$5.33 |
| Q2 2026 | -$3.18 | +$3.53 |
| Q1 2026 | -$7.97 | -$2.70 |
| Q4 2025 | -$9.08 | -$4.35 |
| Q3 2025 | -$7.74 | -$2.88 |
| Q2 2025 | -$6.71 | +$0.11 |
| Q1 2025 | -$5.27 | +$0.22 |
| Q4 2024 | -$4.73 | -$0.46 |
CNNE lost $2.41 per share over the past year, a smaller loss than the year before.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over CNNE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over CNNE on profitability, with a higher operating margin.
CNNE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $68.1M | -36% |
| Q2 2026 | $102.2M | -7.3% |
| Q1 2026 | $96.2M | -6.8% |
| Q4 2025 | $103.3M | -6% |
| Q3 2025 | $106.9M | -23% |
| Q2 2025 | $110.2M | -6.6% |
| Q1 2025 | $103.2M | -1% |
| Q4 2024 | $109.9M | -32% |
CNNE's revenue has slid since its 2020 peak: $68M last quarter, down 36% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -39% | -26 points |
| Q2 2026 | -56% | -0.3 points |
| Q1 2026 | -23% | -2.2 points |
| Q4 2025 | -23% | -3.3 points |
| Q3 2025 | -12% | +0.8 points |
| Q2 2025 | -55% | -36 points |
| Q1 2025 | -21% | +18 points |
| Q4 2024 | -20% | -4.7 points |
CNNE's operating margin was −39% last quarter, down 26 points from the same quarter a year ago.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
CNNE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $28.7M | +$52.8M |
| Q2 2026 | -$8.3M | +$15.3M |
| Q1 2026 | -$23M | -419% |
| Q4 2025 | $12M | +$26.4M |
| Q3 2025 | -$24.1M | +$9.5M |
| Q2 2025 | -$23.6M | -$11.8M |
| Q1 2025 | $7.2M | +$44.5M |
| Q4 2024 | -$14.4M | +$21.9M |
CNNE has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
CNNE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3% | -1.3M shares |
| 1 year | -30% | -18.5M shares |
| 3 years | -44% | -33.1M shares |
| 5 years | -54% | -49.3M shares |
CNNE has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $45.5M |
| Q2 2026 | $32.2M |
| Q1 2026 | $14.7M |
| Q4 2025 | $87.1M |
| Q3 2025 | $119.7M |
| Q4 2024 | $200,000 |
| Q3 2024 | $200,000 |
| Q2 2024 | $231.4M |
CNNE spent $180M buying back its own shares over the past year.
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
CNNE Net Leverage
CNNE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
CNNE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.9 | Neutral |
| Stochastic | 82.0 | Overbought |
CNNE's weekly RSI is 63 (neutral) and its Stochastic is 82 (overbought).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
CNNE PE vs Consumer Cyclical Sector
| Metric | CNNE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
CNNE has no meaningful PE right now: it lost money over the past year.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over CNNE on trend strength, trading above more of its moving averages.
CNNE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.4 | 4.2% above |
| 20 week MA | $15.6 | 9.5% above |
| 50 week MA | $14.6 | 17% above |
| 100 week MA | $16.7 | 2.1% above |
| 200 week MA | $18.3 | 6.7% below |
CNNE has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 6.7% below its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over CNNE on returns for 2026, with the stronger performance.
CNNE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37.3 | $43.6 | +17% |
| 2021 | $43.6 | $36.1 | -17% |
| 2022 | $36.1 | $20.0 | -45% |
| 2023 | $20.0 | $19.5 | -2.4% |
| 2024 | $19.5 | $19.9 | +2% |
| 2025 | $19.9 | $15.9 | -20% |
| 2026 YTD | $15.9 | $17.0 | +7.4% |
CNNE has finished lower in four of the last six years. It's up 7.4% so far in 2026.